Business Context and Reporting Period
Company: pSivida Corp. (Note: Request metadata listed "Eyepoint, Inc.", but the filing text identifies the registrant as pSivida Corp.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Business Overview: pSivida develops sustained-release drug delivery products. Key technologies include Durasert (licensed to Alimera for Iluvien and to Bausch & Lomb for Retisert/Vitrasert) and BioSilicon (lead candidate BrachySil for cancer treatment). The company relies heavily on collaboration agreements with Alimera Sciences and Pfizer for funding and revenue.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2009 | Three Months Ended Sep 30, 2008 |
|---|---|---|
| Total Revenues | $3.38 million | $2.81 million |
| Net Loss | $(1.59) million | $(0.47) million |
| Loss Per Share (Basic/Diluted) | $(0.09) | $(0.03) |
| Operating Cash Flow | $(0.93) million (Used) | $(4.49) million (Used) |
| Cash and Equivalents (End of Period) | $5.96 million | $10.98 million |
| Total Assets | $34.49 million | $37.10 million (Jun 30, 2009) |
| Derivative Liabilities | $2.49 million | $0.97 million (Jun 30, 2009) |
| Accumulated Deficit | $(228.64) million | $(227.05) million (Jun 30, 2009) |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 21% to $3.38 million, driven primarily by the Alimera collaboration agreement (straight-line amortization and note payments).
- Expense Reduction: Total operating expenses decreased 33% to $3.49 million.
- R&D: Decreased 19% due to lower UK-based clinical trial costs and favorable currency exchange rates.
- G&A: Decreased 43% primarily due to the absence of a $633,000 provision for losses on a note receivable recorded in the prior year and reduced legal/audit fees following U.S. reincorporation.
- Derivative Liability Impact: The company recorded a $1.52 million expense related to the change in fair value of derivative liabilities (warrants denominated in Australian dollars), compared to $1.33 million income in the prior year. This volatility is driven by fluctuations in the company's share price.
- Cash Position: Cash decreased by $0.94 million during the quarter, though cash burn from operations improved significantly compared to the prior year.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes cash of $6.0 million is sufficient to fund operations through at least December 31, 2010. This assumption relies on continued funding from Pfizer and Alimera (including note payments and development cost reimbursements).
- Product Milestones:
- Iluvien (Alimera): Phase III interim data expected December 2009. NDA filing expected Q2 2010; FDA response expected Q4 2010 if Priority Review is granted.
- BrachySil (BioSilicon): Dose-ranging clinical trial for pancreatic cancer completed October 2009. Company seeks a development partner for Phase III.
- Risks and Contingencies:
- Derivative Volatility: Future earnings remain sensitive to share price fluctuations due to $2.5 million in derivative liabilities.
- Capital Needs: Future funding beyond late 2010 depends on FDA approval of Iluvien or successful capital raises, which may be dilutive.
- Collaboration Dependence: Financial stability is heavily tied to the continuation of agreements with Alimera and Pfizer.
Investor Verification Checklist
- Derivative Liability Valuation: Verify the sensitivity of the $2.49 million derivative liability to share price changes, as this significantly impacts net loss.
- Alimera Note Payments: Confirm the receipt of scheduled conditional note payments and development cost reimbursements from Alimera, which are critical to the revenue recognition model and liquidity.
- Retisert Royalties: Note that royalty income from Bausch & Lomb is currently deferred; verify the status of the $3.0 million advance payment and the timeline for resuming royalty recognition.
- Cash Runway: Assess the validity of the "12-month funding" assumption given the company's reliance on third-party partners for cash flow.
- Foreign Currency Exposure: Review the impact of the strengthening U.S. dollar on the valuation of UK-based intangible assets (BioSilicon) and operating expenses.